bluuebunny/crossref_metadata_2025_split huggingface dataset:
Clinical benefit of second EGFR-TKI retreatment on overall survival in patients with advanced non-small-cell lung cancer harboring EGFR-mutation positive after failure of the initial EGFR-TKI treatment: A retrospective analysis.
Authors: Nakashima Masanao , Hirose Takashi , Oki Yasunari , Murata Yasunori , Sugiyama Tomohide , Ishida Hiroo , Okuda Kentaro , Yamaoka Toshimitsu , Ohmori Tohru , Ohnishi Tsukasa 
Published: March 2020

e19164 Background: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) bring the best result to EGFR-mutation positive non-small cell lung cancer patients, but most lead to drug resistance. These acquired resistances are associated with T790M mutation or Met amplification, HGF expression. To assess whether affects overall survival in these patients, we did a retrospective study comparing survival outcomes in 2nd EGFR-TKI treated patients with controls without 2nd EGFR-TKI screened during the same time period. Methods: We examined overall survival in thirty-two of 52 patients with advanced, EGFR-mutation-positive NSCLC who treated 1st EGFR-TKI (gefitinib) from January 2009 to December 2012. We identified 16 patients who were given 2nd EGFR-TKI (erlotinib) after failure of the initial gefitinib treatment (retreatment group) with 16 patients who were not given 2nd EGFR-TKI but given only chemotherapy (control group), 20 patients who might treat with 2nd EGFR-TKI or chemotherapy at that time were excluded in progress after failure of the initial gefitinib treatment. To assess differences in overall survival, we assessed subsets of clinically comparable 2nd EGFR-TKI retreatment group. Results: Among 16 patients who were given 2nd EGFR-TKI, retreatment group who were given one or two cytotoxic chemotherapy from 1st EGFR-TKI to 2nd EGFR-TKI, median overall survival from initiation of the diagnosis with advanced IIIB/IV stage or surgical recurrent NSCLC was 24.2 months. 16 patients of control group who were given from second to seven line cytotoxic chemotherapy, overall survival was 15.8 months (p=0.021). Retreatment group who were given 2nd EGFR-TKI was significantly longer than control group in EGFR mutation positive patients. Response rate and disease control rate with 2nd EGFR-TKI retreatment are 12.5% and 31.3%. Conclusions: In patients with advanced, EGFR mutation positive NSCLC, retreatment group who were given 2nd EGFR-TKI therapy was associated with improved survival compared with control group who were given only cytotoxic chemotherapy.
The efficacy of PEG-Asp-argase-based chemotherapy for nasal-type extranodal NK/T-cell lymphoma.
Authors: Wen Jing-Yun , Li Mai , Li Xing , Lin Qu , Dong Min , Ruan Dan-Yun , Wu Xiang-Yuan 
Published: March 2020

e19504 Background: Nasal-type extranodal NK/T-cell lymphoma (ENKL) is a highly invasive disease with quite poor prognosis.Pegaspargase (PEG-Asp) displays a similar anti-cancer mechanism as that of L-asparaginase (L-ASP), but exhibits lighter antigenicity. The aim of the present research was to evaluate efficacy and safty of PEG-Asp-based regimen in ENKL. Methods: Data were collected from 23 patients with histologically confirmed ENKL who were admitted to the Third Affiliated Hospital of Sun Yat-Sen University from January 2009 to March 2012. Each patient received PEG-Asp 2500 IU/m2/IM on day 1 of each 21-day chemo-cycle. Among them, 8 received combination chemotherapy with CHOP regimen, 11 with EPOCH, and 4 with a CHOP-like regimen (CHOP + bleomycin). The CHOP regimen consisted of cyclophosphamide 750mg/m2, IV (day 1), pirarubicin 40mg/m2, IV (day 1), vincristine 1.4 mg/m2, IV (day 1), and prednisone 100mg, oral (days 1- 5). The EPOCH regimen consisted of etoposide 50mg/m2, epidoxorubicin 12 mg/m2 and vincristine 0.4mg/m2 dissolved in 500mL saline and administered as a continuous IV drip for 24 hours on days 1- 4. Cyclophosphamide 750mg/m2, IV (day 5) and prednisone 60mg/m2, oral (days 1-5), were also administered. In the CHOP-like regimen, bleomycin 15mg was added on days 1-3. Stage I-II patients received local radiotherapy after the chemotherapy. Results: The patients received the PEG-Asp-based chemotherapy for 2-5 cycles (median, 4 cycles). Eleven (47.8%) achieved complete response (CR), and the overall response rate (ORR) was 82.6%. The median time to progression (TTP) was 5 months (range, 2-6 months) and the median OS was 16 months (range, 5-38 months). The 1-year and 2-year survival rate were 82.6% (19/23) and 56.5% (13/23) , respectively. A minor glutamic-pyruvic transaminase (GPT) elevation was observed in 3 patients (13.0%), slight decrease of albumin in 3 (13.0%), reduced fibrinogen level in 2 (8.7%), grade I-II WBC bone marrow suppression in 8 (34.8%), and grade III-IV WBC bone marrow suppression in 3 (13.0%). No allergic incidences were witnessed. Conclusions: Our results suggested PEG-Asp-based chemotherapy presented potential effects in treating nasal-type ENKL with acceptable side effects profile.
Epidemiologic findings of non-Hodgkin lymphoma (NHL) in Puerto Rico (PR).
Authors: Ortega Jose Luis , Tirado-Gomez Maribel , Cabanillas Fernando , Rivera-Rodriguez Noridza , Torres Carlos , Ortiz Karen 
Published: March 2020

e19505 Background: NHL was the 6th leading cause of cancer among USA Hispanics from 2005-2009. There is limited literature about lymphoma among Hispanics outside USA. The goal of this study is to assess the incidence, trends, survival and histological distribution in a population of Puerto Ricans and compare the results with USA. We report data on 3,184 pts diagnosed with lymphoma from the PR Cancer Center Registry during 2004-2009. Methods: Rates of sex-specific, age-adjusted incidence (AAIR) with 95% CI were estimated and standardized by age-adjustment according to the world standard population. The annual percent change (APC) using joint point regression analysis was determined. Data was compared with the SEER Cancer Statistic Review (1975-2009). Results: NHL comprises 82% of lymphomas in PR. As in USA it is the 6th most common cancer in males and the 7th in females. AAIR per 100,000 for NHL in PR was lower as compared to USA: 11.8 for males in PR vs 23.2 in USA, while for females it was 9.8 in PR vs 16.2 in USA. Despite a lower AAIR, there was an increase of 3.2% APC in NHL for PR during 2004-09. When analyzed according to gender, this rise was attributed only to females: 6.3% increase vs 0.5% in males. In contrast, in USA a decreasing trend in APC (-0.8%) was seen for females. B cell lymphomas in PR comprise 92% of NHL and 90% in USA. DLBCL represents 53% of all B cell-NHL in PR which is markedly higher than the 28% reported in USA. Follicular NHL in PR represents 22% of all NHL, in contrast to 32% in USA. There is a noticeable difference in the distribution of T cell lymphoma subtypes in PR as compared with USA, with a higher number of cases of anaplastic large cell and cutaneous T cell lymphomas and a lower frequency of angioimmunoblastic T cell lymphomas in PR. In terms of relative survival rate (RSR), our results are comparable to USA. Follicular NHL has a 5 year RSR of 74% in PR vs 75% in USA and DLBCL has a 5 year RSR of 47% in PR, vs 50% RSR in USA. Conclusions: Despite a lower AAIR, a significant increasing trend of NHL was observed in PR and we determined this to be exclusively observed among females. We also identified marked differences between the distribution of histologic subtypes of NHL in PR and USA. We plan to assess which histologic subtypes are increasing and in which regions of the island.
MicroRNA profiles (including 370 miRNAs) in lymphomas.
Authors: Paydas Semra , Acikalin Arbil , Ergin Melek , Celik Hikmet , Yavuz Basak , Tanriverdi Kahraman 
Published: March 2020

e19512 Background: MicroRNAs (miRNAs) are small noncoding RNAs and they control the expression of protein-coding genes. Deregulation of miRNAs has been found to be associated with the pathogenesis and prognosis of various diseases including malignant tumors. In this study cancer related 370 miRNAs, which are most commonly related with cancer, have been explored in 88 cases with diffuse large B cell lymphoma (DLBCL) and 32 cases with Hodgkin’s lymphoma (HL). Sixty samples taken from cases with reactive lymphadenopathy have been used as control. Quantitative miRNA results were compared with lymphoma entities and also with controls. Methods: Samples taken from 88 cases with DLBCL and 32 cases with HL were used as study material. QPCR method was used to profile 370 miRNAs. Biogazelle qbasePLUS 2.0 software was used for analysis of the results. Global mean normalization method used for normalization of the individual miRNA expression levels. Mann-Whitney U test was used and p>0.05 was evaluated as statistically important. Results: miR -41-5p, miR-494, miR-10a-5p, 340-5p, miR-155-5p, miR-500a-5p, miR-148b-3p, miR-330-3p, miR-191-5p, miR-193b-3p, miR-92a-3p, miR-34a-5p, miR-99b-5p, miR-671-3p were found to be increased in cases with DLBCL as compared with controls. miR-370, miR-155-5p, miR-372, miR-93-5p, miR-324-3p, miR-34a-5p were found to be increased in cases with HL as compared with controls. miR-320a, miR-889, miR-126-3p, miR-370, miR-138-5p, miR-29a-3p, miR-339-3p, miR-93-5p, miR-324-3p, miR-345-5p were found to be increased in cases with DLBCL as compared with HL. Conclusion: miRNA profile of DLBCL has been previously studied. However there is limited information about miRNA profile of HL. Our method for miRNA profiling is qPCR and it is the gold standard for miRNA profiling currently. Studies which has comprehensive numbers of miRNAs are mostly microarray based studies. Becuase of short sequence of miRNAs, microarray method doesn’t perform as good as in gene expression studies especially in low expressed miRNAs. In our best knowledge our study is the most comprehensive qPCR miRNA profiling study in HL and NHL. In further step we would like to compare miRNA profile and clinic-prognostic parameters.
Prevalence of autoimmune conditions in patients with Waldenstrom macroglobulinemia: Exploratory analysis of a series of consecutive patients.
Authors: Atienza Jonessa , Codreanu Ion , Varilla Vincent , Reale Michael A. , Silver Joel , Pazooki Mohammad , Dasanu Constantin 
Published: March 2020

e19514 Background: Literature suggests association between Waldenström macroglobulinemia (WM) and autoimmune conditions which may share the same pathogenesis. We identified the prevalence of autoimmune phenomena in WM patients and compared it with the general population. Methods: We conducted retrospective and prospective analyses in a series of patients (n=12) with WM followed in outpatient setting. The median age was 74 years. The charts were reviewed for autoimmune abnormalities; length of prospective analysis segment was circa 24 months. The prevalence of autoimmune disorders was compared with the general population. Statistical analysis: Findings were tested for statistical significance using Fisher’s exact test for small number of observations (95% confidence); p value < 0.05 considered significant. Results: Circa 58.3% patients had autoimmune disorders (Table). These include Hashimoto thyroiditis, pernicious anemia, immune thrombocytopenia (ITP), autoimmune hemolytic anemia (AIHA), chronic inflammatory demyelinating polyneuropathy (CIDP), pure red cell aplasia (PRCA), polymyalgia rheumatica (PMR), temporal arteritis, and ANA positivity. The Table summarizes the statistical analysis of each autoimmune condition with their respective p values. Conclusions: More than 50% of patients had autoimmune conditions, significantly exceeding overall prevalence in general population. Statistically significant differences noted for pernicious anemia, Hashimoto thyroiditis, ITP, AIHA, CIDP, PRCA, and temporal arteritis. The difference was not significant for PMR and ANA positivity. However, analysis of larger cohorts is needed to confirm our observations. [Table: see text]
Feasibility of highly intensive chemotherapy for AIDS-related Burkitt lymphoma.
Authors: Kojima Yuki , Moritani Suzuko , Nakamura Hiroyuki , Yamamoto Hideyuki , Miyata Yasuhiko , Iida Hiroatsu , Ohashi Haruhiko , Nagai Hirokazu 
Published: March 2020

e19521 Background: Burkitt lymphoma (BL) progresses very rapidly, but highly intensive chemotherapy (e.g. CODOX-M/IVAC, hyper-CVAD/MA) has been shown to be a promising strategy. In this time, AIDS-related lymphoma is treated with similarly to non-AIDS lymphoma, nevertheless it is not clear whether the highly intensive regimens are feasible and beneficial for AIDS-related Burkitt (AIDS-BL) or not. The purpose of the current study is to compare the toxicity of AIDS-BL to non-AIDS-BL retrospectively. Methods: We collected the data of all patients (pts) with BL between 2004 and 2011 at our institution. Chart review was performed for all identified pts. The effects of treatment and the clinical variables on overall survival (OS) were assessed. Results: We identified 25 Burkitt lymphomas, and a total of 108 cycles of highly intensive chemotherapy were administered. Nine of these 25 were AIDS-BL (median age, 51; range, 36 to 68) and 16 were non-AIDS-BL (median age, 60; range, 27 to 75). As chemotherapeutic regimens, 15 (60%) were treated with CODOX-M/IVAC, 8 (32%) with hyper-CVAD/MA, and 2 (8%) with EPOCH. Of 12 pts (48%) treated with rituximab-contain regimens. Completion rate of planned chemotherapy was 64%. The median follow-up was 34.3 months. Three-year OS was 73.6%. There were no significant differences in OS between chemotherapeutic regimens (p=0.94) and between AIDS-BL and non-AIDS-BL (p=0.39). The overall incidence of grade 3/4 febrile neutropenia was 64.8% (70 of 108 cycles), 60.5% for HIV-infected and 67.7% for HIV-negative case, respectively. Grade 4 thrombocytopenia was frequently observed in AIDS-BL (72.1% vs. 40.0%), and incidence of grade 3/4 anemia was not different (79.1% vs. 70.8%). Conclusions: This study showed that clinical outcomes, including toxicities, of AIDS-BL were similar to non-AIDS-BL when BL treated with highly intensive chemotherapy.
Lenalidomide and dexamethasone in overtreated multiple myeloma patients: A single center update.
Authors: Moscetti Alessandro , De Benedittis Daniela , Resci Federica , Antolino Giusy , Bianchi Maria Paola , Naso Virginia , La Verde Giacinto 
Published: March 2020

e19527 Background: Lenalidomide (Len - Revlimid) is a therapeutic option for relapsed and refractory multiple myeloma, especially in association with steroids. Methods: Oraldaily lenalidomide (10-25 mg) for 21 days every month (median courses 9.7) and weekly dexamethasone (Dex) were administered until progression in 41 pretreated patients (median age 66.2 yrs) observed between June 2008 and January 2013 at Hematology Department of Sant’Andrea Hospital in Rome. Past treatment included alkylants, anthracyclines, IFN-α, thalidomide, bortezomib and single or double autograft. Twenty five patients were evaluated after 6 courses of therapy, administered as second to fifth line, and prospectively followed-up; two patients weren’t considered because of early death. Treatment response was assessed according to IMWG uniform response criteria. Results: The overall response rate was 56% (14/25 pts) with a median duration of response of 13 months: 1 patient reached CR, 1 VGPR, 12 patients reached a partial response (PR), 10 showed a stable disease (SD) and 1 progressive disease (PD). The median progression free survival was 14.8 months. Among responder patients, 4 died due to progression disease after a median of 16.5 courses, while 9 are in continuous treatment (3 with over 33 courses each) and 1 in salvage therapy; among non responder ones, 7 died for PD, while 3 are in continuous treatment and 1 in salvage therapy. The reported side effects included pneumonia, neutropenia, diarrhea, peripheral sensitive polyneuropathy, transient liver failure, lower urinary tract infection, skin rash, transient aphasia, conjunctival hemorrhage and deep vein thrombosis, all resolved with brief discontinuance and specific support therapy without hospitalization. Conclusions: This study shows that Len-Dex combination is an effective oral salvage therapy with good response rate and manageable side effects for relapsed and refractory multiple myeloma patients.
Morphologic pattern of CD30 distribution within neoplastic cells in Hodgkin lymphoma.
Authors: Paszkiewicz-Kozik Ewa , Rymkiewicz Grzegorz , Osowiecki Michal , Romejko-Jarosinska Joanna , Walewski Jan Andrzej 
Published: March 2020

e19535 Background: CD30 protein is expressed on Hodgkin and Reed-Sternberg (HRS) cells in nearly all cases of classical Hodgkin lymphoma (HL). CD30 is present on a cell membrane and on the Golgi complex of the endomembrane cell system. Given the growing clinical application of CD30 targeting we were interested to see if there is variability in distribution of CD30 protein between the cell surface and the cytoplasm. External exposure of CD30 is most likely a critical condition of successful interaction with the ligand and possibly, a predictive factor for response to CD30 antibody. To our knowledge, clinical data on CD30 expression have not yet been published in the context of cell topography. Methods: The CD30 protein was evaluated in formalin-fixed paraffin-embedded (FFPE) tissue sections by immunohistochemistry (IHC) with monoclonal mouse anti-human antibody CD30 (clone Ber-H2) (Dako). IHC was performed using the EnVision Plus Detection Systems LSAB kit (Dako Corp., Carpinteria, CA), and an antigen-retrieval technique was applied. Morphological pattern (localization of CD30) of CD30 expression was evaluated in each case under a microscope examination. Results: FFPE tissue specimens from 83 newly diagnosed and relapsed (n=78 and n=5, respectively) HL patients were examined. The average (range) of patient age was 39 (18-89), male/female ratio was 1/0.88. Histological subtypes of HL were nodular sclerosis in 87%, mixed cellularity in 8%, lymphocyte rich in 3% of cases, and 1 case of lymphocyte-depleted classical HL. Immunophenotype was typical of classical HL, and HRS cells were positive for CD30 in all cases. Immunostaining for CD30 was present on the Golgi body in 98% of cases, and it was demonstrated on the cell membrane in 27% of cases. Conclusions: In our series of 83 patients with classical HL, predominant pattern of CD30 expression was cytoplasmic (Golgi body), and only 27% of cases demonstrated cell surface expression. We hypothesize that cell surface expression of CD30 protein might predict a response to anti-CD30 antibody that is in the order of magnitude of 30% complete remissions in recurrent HL.
Early lymphocyte recovery (ELR) impact on disease outcome following autologous hematopoietic stem cell transplantation (HDT/ASCT) for multiple myeloma (MM) in the era of novel agents.
Authors: McDuffie Jeremy Scott , Savani Bipin N. , Chinratanalab Wichai , Goodman Stacey , Greer John P. , Oluwole Olalekan O. , Engelhardt Brian G. , Jagasia Madan H. , Kassim Adetola 
Published: March 2020

e19539 Background: Absolute lymphocyte count (ALC) > 500 cells/ µL on day 15 (ELR+) after HDT/ASCT, has been reported to be an independent prognostic indicator, for improved OS and PFS in patients with MM. Novel agents (immunomodulatory drugs (IMiDs) and proteasome inhibitors), mediate there effect through T-cell stimulation, NK cell activation, anti-proliferation, and are now main stay of therapy for MM. We sought to determine their effects on ELR, and correlated to disease outcome. Methods: A retrospective review of all MM patients seen at our institution undergoing HDT/ASCT from January 2008 to December 2012 was performed. Patients were identified from our CIBMTR database. ALC was determined pre-HDT/ASCT (T1), on day15 (T2) and d30 (T3) post-HDC/ASCT. No restrictions on inclusion were made based upon the International Myeloma Working Group response criteria. All had novel agents as part of their initial induction regimen. Disease response was determined by standard clinical and laboratory CIBMTR response criteria, and minimal residual disease status (MRD) by multiparameter flow cytometry. Results: In our study (n= 184), 52/184 patients had ELR+ while 132/184 had ALC < 500 cells/mL (ELR-) at T2. 21% received IMiDs, 33% proteasome inhibitor and 46% combination therapies. 52% of the ELR+ patients were MRD negative (-) at T1, and improved to 74% and 89% at D100, and 1 year post-HDC/ASCT respectively. Similarly 63%, 70%, and 80% of the ELR- patients, were MRD (-) at similar time-points. Chi squared analysis showed no significant difference in rates of MRD (-) based on ELR. ELR also had no impact on disease status as determined by CIBMTR response criteria, or 1 year PFS and OS (p = 0.383), (p = 0.577) respectively. Multivariate analyses, using cox-regression showed no impact of ALC at T1, T2, T3, age, sex, race, cytogenetic risk, or disease stage on disease outcome. Conclusions: Novel agents improve disease control independent of ELR following HDC/ASCT. Understanding their biologic effect on immune-reconstitution will provide a platform for adoptive immunotherapy to better target minimal residual disease.
Assessment of viable cells as a predictor of response in soft tissue sarcomas treated with neoadjuvant therapy.
Authors: Batista Ranyell Spencer Sobreira , Aguiar Samuel , Cunha Isabela Werneck , Lopes Ademar , Soares Fernando A. , Stevanato Paulo Roberto , Mello Celso Lopes 
Published: March 2020

e21507 Background: Soft Tissue Sarcomas (STS) are an uncommon neoplasm with many histological subtypes with different behaviors, response to treatments and developments. The treatment of these tumors is using surgery, radiotherapy or chemotherapy. The pathological response using degree of tumor necrosis has been implicated in survival rates. However comes to assessing the degree of tumor necrosis in the surgical specimens as response parameter could be confuse because the high-grade sarcomas exhibit a high rate of necrosis even without any treatment. Methods: 31 patients with STS of high grade located in extremities treated with neoadjuvant doxorubicin and ifosfamide were observed prospectively since January 2005 to June 2011. For evaluation of surgical specimens post neoadjuvant chemotherapy, a slice of the specimen in with lower gross of necrosis was represented and after mapped evaluating grade of necrosis, fibrosis and percentage of viable cells. Results: Six patients had ≤5% of viable cells, eight had ≤10% and 12 with 30% or less in the sample. Overall survival (OS) was 100%, 100% and 91% with Disease free survival (DFS) were 100%, 85.7% and 82.5%, respectively. No patient had ≥95% necrosis in the surgical specimens considering that a large part of the tissue had fibrosis in patients with few viable cells, which do not correlate with survival. Conclusions: The viable cell count in the sample is feasible, and relates well with survival. We consider this the ideal method for response evaluation in SPM instead of counting necrosis. In combination with the literature data we suggest cutoff points of 5%, 10% and 30%.